Industry

Drug recall: Glenmark, Strides Pharma, Cipla recalled these drugs

There were complaints regarding "defective container closure," it added. The affected lot was manufactured in India and marketed in the US by Cipla USA, Inc.

The Health Master

August 22, 2022

804

Last Updated on October 10, 2024 by The Health Master

New Delhi: Drug makers Glenmark, Strides Pharma, and Cipla are recalling products in the US, the world’s largest market for medicines, due to manufacturing issues.

Glenmark

As per the latest Enforcement Report issued by the US Food and Drug Administration (USFDA), New Jersey-based Glenmark Pharmaceuticals Inc. is recalling over 72,000 units of blood pressure-lowering drugs due to packaging issues.

The USFDA noted in its report that the company, a subsidiary of a Mumbai-based drug firm, is recalling the affected lot due to “blister package issues.”

The lot was produced at Glenmark’s Pithampur (Madhya Pradesh)-based manufacturing facility. The USFDA stated that Glenmark initiated the Class II nationwide (US) recall on June 29 of this year.

Click for more on Drug Recall

Strides Pharma

On a separate note, the US health regulator said a unit of Bengaluru-based Strides Pharma Science is recalling 1,032 bottles of Prednisone tablets, a medication used to treat many conditions, including asthma, allergic reactions, arthritis, and inflammatory bowel diseases, among others.

The affected lot was produced by Strides Pharma Science and marketed in the US by New Jersey-based Strides Pharma Inc.

As per the USFDA, the company is recalling the affected lot due to the “presence of foreign tablet: 2.5 mg tablet in a 20 mg bottle of Prednisone tablets”.

The company initiated the Class II voluntary nationwide recall on July 19 this year.

Click for more on USFDA

Cipla

As per the USFDA, homegrown drug major Cipla is recalling 7,992 bottles of Difluprednate Ophthalmic Emulsion, used to treat swelling and pain after eye surgery, in the US market.

The USFDA stated that New Jersey-based Cipla USA, Inc., a unit of a Mumbai-based drug maker, is recalling the lot due to a “lack of assurance of sterility,” the USFDA stated.

There were complaints regarding “defective container closure,” it added. The affected lot was manufactured in India and marketed in the US by Cipla USA, Inc.

As per the USFDA, a Class II recall is initiated in a situation in which the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

The US is by far the largest market for pharmaceutical products in the world. In the last financial year, India’s pharma exports stood at around USD 24.62 billion, with the US, UK, South Africa, Russia, and Nigeria emerging as the top five destinations.

Other drugs recall

Drug recall: Glenmark, Sun, Dr Reddy’s recalled these Drugs

Drug recall: Atorvastatin 40 mg tablets recalled due to this reason

Drug recall: Magnesium Citrate Oral Solution recalled due to this reason

Drug recall: Propofol Injectable Emulsion recalled due to this reason

Drug recall: Insulin Glargine Injection Pens recalled due to this reason

Drug recall: Morphine Sulfate 30 mg, 60 mg Extended Release Tablets recalled due to this reason

Also read

DCGI approves olaparib as monotherapy for high-risk early breast cancer

USFDA issues Form 483 with 6 observations to Sun Pharma

Anti-dumping duty recommended on Ofloxacin & its intermediates imported from China

IPC clarifies: General Chapter on ‘Uniformity of Dosage Units’ in IP 2022 not mandatory